AbbVie Background
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Through a detailed examination of AbbVie, we can deduce the following trends:
Debt To Equity Ratio
The debt-to-equity (D/E) ratio helps evaluate the capital structure and financial leverage of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing AbbVie against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
-
When evaluating the debt-to-equity ratio, AbbVie is in the middle position among its top 4 peers.
-
The company maintains a moderate level of debt relative to its equity with a debt-to-equity ratio of 10.42, suggesting a relatively balanced financial structure.
Key Takeaways
For AbbVie, the PE, PB, and PS ratios are all high compared to its peers in the Biotechnology industry, indicating potentially overvalued stock. On the other hand, AbbVie's high ROE, EBITDA, and gross profit suggest strong profitability and operational efficiency relative to industry peers. However, the low revenue growth rate may raise concerns about the company's future performance compared to its competitors in the sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
